Therapeutic Advances in Musculoskeletal Disease

Papers
(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis126
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study70
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome39
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis39
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment29
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI29
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients27
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients26
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data26
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis25
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review25
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)25
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials24
Cardio-rheumatology: integrated care and the opportunities for personalized medicine24
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors24
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry22
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study22
Health disparities in rheumatoid arthritis21
Calcineurin inhibitors in systemic sclerosis – a systematic literature review21
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids20
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs20
0.19474005699158